

E1 exhibits the same conformation as an L1 major capsid protein expressed on the surface of intact human papillomavirus virions
intact, native human papillomavirus virions.

E2 12. (Thrice Amended) A vaccine for the prevention of papillomavirus infection, said vaccine comprising at least one [PV type of] recombinantly produced human papillomavirus (PV) L1 protein, or antigenic fragment thereof, which protein or antigenic fragment [is capable of reproducing] reproduces the antigenicity and exhibits the same conformation as [the] an L1 major capsid protein expressed on the surface of intact, native human papillomavirus virions.

E3 19. (Twice Amended) A method for protecting [an animal] a human against a papillomavirus infection, said method comprising administering a therapeutically effective amount of a vaccine, wherein said vaccine comprises at least one [PV type of] isolated recombinantly produced human papillomavirus (PV) L1 protein or antigenic fragment thereof, [which] wherein said protein or antigenic fragment [is capable of reproducing] reproduces the antigenicity and exhibits the same conformation as [the] an L1 major capsid protein expressed on the surface of intact, native human papillomavirus virions.

Kindly add the following claims:

E4 --50. A vaccine for the prevention of human papillomavirus infection, said vaccine consisting essentially of at least one isolated recombinant papillomavirus (PV) L1 protein, or antigenic fragment thereof, which protein or antigenic fragment reproduces the antigenicity

I
and exhibits the same conformation as an L1 major capsid protein expressed on the surface
intact
of ~~intact, native~~ human papillomavirus virions.
A

E 4
51. The vaccine of Claim 50, wherein said human papillomavirus is selected from the group consisting of HPV 1, 2, 3a, 4, 5, 6b, 7, 8, 9, 10, 11a, 12, 13, 16 and 18.

52. The vaccine of Claim 50 wherein the human papillomavirus is either HPV-6 or HPV-11a.

53. A method for protecting a human against a papillomavirus infection, said method comprising administering a therapeutically effective amount of a vaccine according to Claim 50.

54. A method for protecting a human against a human papillomavirus infection, comprising administering to a human subject a therapeutically effective amount of a vaccine according to Claim 51.

55. A method for protecting a human against a human papillomavirus infection, comprising administering to a human subject a therapeutically effective amount of a vaccine according to Claim 52.